Retina

What to investigate: aqueous, vitreous or both?

The incidence of retinal haemorrhages in abusive head trauma in paediatric patients for known perpetrators, regardless of a confession, is similar, reveals a paper.

Aflibercept 2.0 mg may be beneficial for cases of exudative AMD unsuccessfully treated with ranibizumab or bevacizumab, according to a recent retrospective review.

Wavelet augmented ultrasound effectively detects differences in choroidal microarchitecture in eyes with wet and dry AMD, according to a recent paper.

A new implant that allows patients suffering from advanced age-related macular degeneration (AMD) to improve their general vision and regain independence is now being implanted in the UK.

Repeated pars plana vitrectomy, with internal limiting membrane peeling and gas tamponade, is a safe and effective treatment technique for persistent macular holes, states an investigation in the Journal of Retinal and Vitreous Diseases.

Long-term positive outcomes of a minimally invasive retrobulbar episcleral brachytherapy device (SalutarisMD, Salutaris Medical Devices, London, UK) show promise for treating wet age-related macular degeneration (wAMD), according to data presented at the RCO congress.

JETREA (ThromboGenics, Leuven, Belgium) has launched in Denmark and Sweden with roll out of the drug to follow shortly in Finland and Norway. These launches will be performed by ThromboGenics partner, Alcon.

Primary endpoint results, demonstrating the non-inferiority of the BIOTRONIK Orsiro hybrid drug-eluting stent compared to Abbott?s XIENCE PRIME, from the BIOFLOW-II clinical study have been revealed at the EuroPCR congress in Paris.

The National Institute for Health and Care Excellence (NICE) has announced that Eylea (aflibercept, Bayer HealthCare, Leverkusen, Germany) should be recommended for the treatment of patients with wet age related macular degeneration (wAMD).

The variable duty cycle (DC) control on dual pneumatic ultra high-speed 23G cutters has an important effect on the vitreous flow but this is reduced at high cut rates as a result of convergence, reveals a paper in Retina.

Digital devices may be used as a visual rehabilitation technique for low-vision AMD patients, according to a paper featured in the journal Eye.

Macular thickness significantly increases up to six months after uncomplicated cataract surgery, according to an investigation featured in the journal Eye.

Increased oral supplementation of carotenoids (lutein and zeaxanthin) and omega-3 fatty acids, found in fish oil, does not reduce the risk of AMD progression further to the original AREDS formulation, claims the latest results of the Age-Related Eye Disease Study (AREDS2).

Iluvien has been used to treat a diabetic macular oedema (DME) patient in the UK since the product became commercially available, it was revealed in a press release this week.

Iluvien, an intravitreal implant, is now available as a treatment for chronic diabetic macular oedema (DME) in the UK.

Parkinsons disease (PD) is associated with retinal nerve fibre layer (RNFL) loss and retinal thinning and can be detected by Fourier-domain OCT, claims a new study.

Focal photocoagulation may be a less invasive method for the treatment of microaneurysms, according to a paper published in the journal Retina.

Ranibizumab has been recommended for use within the NHS in England and Wales to treat macular oedema (ME) secondary to retinal vein occlusion (RVO).

Intravitreal bevacizumab is not recommended for the treatment of new onset Nonarteritic Anterior Ischemic Optic Neuropathy (NAION).

Intravitreal bevacizumab is well tolerated and causes the regression of abnormal diabetic neovascularization, according to recently published data.

Unoprostone will begin patient enrolment for the Phase III clinical study for the treatment of retinitis pigmentosa (RP), claims the latest press release.

Low-fluence photodynamic therapy (PDT) decreases subfoveal choroidal thickness (SFCT) in central serous chorioretinopathy (CSC), states a paper in the journal Eye.

Oral drug fenretinide has potential for the treatment of geographic atrophy (GA), but further studies are required.

Duration of disease should be considered when offering vein occlusion patient treatment